anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the novel technical field of medicament and specifically relates to a preparation method of manidipine sustained release tablets and use thereof. The tablets are used for treating high blood pressure. The novel dosage form is characterized in that the products are sustained release tablets. Each tablet contains manidipine 10mg-100mg, preferably 20mg-60mg. The objective of the invention is to provide sustained release tablets having good stability, high quality and obvious curative effect, and taking manidipine as a main medicament, and preparation method thereof. The inventive Chinese traditional medicine is slowly released so as to maintain relatively stable blood concentration and longer action time, and has advantages of reducing side effect, more convenient administration etc.
A method for treating a patient suffering from diabetes mellitus by delivering aerosolized insulin to the patient and a programmed, portable, hand-held device used in such treatment methodology is disclosed. Two basic types of drug delivery devices are disclosed for use in connection with the present invention. In accordance with the first type of device the insulin is contained within a low boiling point propellant which is held within a canister under pressure. In accordance with the second type of device the insulin is present within a container in solution and the solution is moved through a porous membrane to create an aerosolized formulation which is inhaled by the patient. In accordance with both devices a measured amount of insulin containing formulation is automatically released into the inspiratory flow path of a patient in response to information obtained from determining the inspiratory flow rate and inspiratory volume of a patient. The determination of values and release of drugs are carried out in real time. Reproducibly dosing of insulin to the patient is obtained by repeatedly providing for automatic release of insulin formulation at the same inspiratory flow rate and inspiratory volume. To maximize the efficiency of the delivery of the insulin formulation the formulation is released at an inspiratory flow rate in the range of from about 0.1 to about 2.0 liters/second and a measured inspiratory volume in the range of about 0.1 to about 0.8 liters.
In this group, Patients receive Conventional Therapy for 40 minutes daily and 5 days in a week. The training period was 5 week after the recruitment of patients.
Prospective memory (PM) is the ability to remember an intention in the future. Individuals with depression are candidates for PM failures, resulting in detrimental consequences, such as forgetting to take a medication or implement therapeutic techniques; inaccurate assessments of one's PM abilities can exacerbate these issues. The current study examined if appraisals about one's prospective memory (meta-PM) performance differs between healthy and depressed adults. Data were gathered from 137 adults and included self-reported depression, PM beliefs, objective PM, and assessment of executive functions (EFs). Participants were separated into depressed/healthy categories based on a self-report measure. There was a non-significant correlation between self-reported PM and objective PM for both depressed (r = .06, p = .61) and healthy (r = .08, p = .52) groups, suggesting both groups had inaccurate meta-PM. There were non-significant differences in meta-PM between these groups (Fisher's Z = -0.09, p = .93), but exploratory gender analyses revealed women's meta-PM was significantly less accurate than men's. Women had higher reports of depression and PM complaints compared to men. This study lends evidence that depression is not necessarily related to worse meta-PM accuracy, despite depression's association with memory complaints, and that women are at greater risk for inaccurate meta-PM.
Background: End stage renal disease (ESRD) is a global public health issue. The dialysis therapy brings huge economic burden to many countries. According to the report of 2015 United States Renal Data System (USRDS), the incidence rate of ESRD is 458 people per million populations. And the prevalence rate is 3,138 people per million populations, which is the highest one in the world. Chronic kidney disease (CKD) can be classified into five stages according to glomerular filtration rate. Whatever the stage it is, patients should keep healthy habits about diet and exercise and good adherence to medication. If patients are able to monitor their lifestyle, it not only promotes health, but also reduces the cost of health care.

Aim: By application of wearable devices and health management platform to build self-management model in CKD patients and analyze the cost of healthcare.

Material and Methods: The investigators plan to recruit 60 CKD patients as trial subjects. The intervention group is composed of 30 participants, and the control group 30 participants. The intervention group received intervention with wearable devices and health management platform for 90 days. Patients record their own diet diary by a smartphone application, and their exercise-related data are collected by wearable devices. Then, all the collected information will be upload to health management platform. The investigators also create a LINE group to encourage exercise in the experimental group. The investigators compare the scores of self-management sheet and physical and laboratory examinations before and after the intervention. The investigators also analyze the cost of healthcare within 180 days.
Patients with impaired gag reflex or other swallowing abnormalities are at risk for regurgitation or aspiration of PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution. Observe these patients during the administration of PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution. Use with caution in these patients. 

Do not combine PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution with starch-based thickeners [see Dosage and Administration (2.1)]. Polyethylene glycol (PEG), a component of PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution, when mixed with starch-thickened liquids reduces the viscosity of the starch-thickened liquid. When a PEG-based product used for another indication was mixed in starch-based pre-thickened liquids used in patients with dysphagia, thinning of the liquid occurred and cases of choking and potential aspiration were reported.
The invention relates to the technical field of daily chemicals, and provides a hair dyeing composition, a preparation method and application thereof, and a hair dyeing mousse, wherein the hair dyeing composition comprises a No. 1 agent and a No. 2 agent, and the No. 1 agent comprises the following raw materials in parts by weight: 0.1 to 0.5 part of thickener, 0.5 to 10 parts of emulsifier, 0 to 8 parts of hair dye, 3 to 8 parts of pH regulator, 0.5 to 4 parts of antioxidant, 0.1 to 2 parts of physical foaming agent and 50 to 80 parts of water; the agent No. 2 comprises the following raw materials in parts by weight: 0.1 to 0.5 part of thickener, 0.5 to 10 parts of emulsifier, 6 to 12 parts of oxidant, 0.5 to 3 parts of stabilizer, 0.1 to 2 parts of physical foaming agent and 60 to 80 parts of water. The hair dyeing composition reduces the use amount of the physical foaming agent, ensures that the composition slurry and the physical foaming agent are mixed more uniformly, the system is more stable and efficient, and the sprayed foam is fine and uniform, has smaller and more solid foam volume, can be densely covered on the surface of hair, and has good adhesive force, good hair dyeing effect and high uniformity when being applied to hair dyeing mousse.
Disulfiram produces a sensitivity to alcohol which results in a highly unpleasant reaction when the patient under treatment ingests even small amounts of alcohol.

Disulfiram blocks the oxidation of alcohol at the acetaldehyde stage. During alcohol metabolism following disulfiram intake, the concentration of acetaldehyde occurring in the blood may be 5 to 10 times higher than that found during metabolism of the same amount of alcohol alone.

Accumulation of acetaldehyde in the blood produces a complex of highly unpleasant symptoms referred to hereinafter as the disulfiram-alcohol reaction. This reaction, which is proportional to the dosage of both disulfiram and alcohol, will persist as long as alcohol is being metabolized. Disulfiram does not appear to influence the rate of alcohol elimination from the body.

Disulfiram is absorbed slowly from the gastrointestinal tract and is eliminated slowly from the body. One (or even two) weeks after a patient has taken his last dose of disulfiram, ingestion of alcohol may produce unpleasant symptoms.

Prolonged administration of disulfiram does not produce tolerance; the longer a patient remains on therapy, the more exquisitely sensitive he becomes to alcohol.
Metaxalone tablets, USP contain 400 mg of metaxalone and the following inactive ingredients: alginic acid, FD&C Yellow No. 06 Aluminum Lake, lactose monohydrate, magnesium stearate, povidone and propylene glycol alginate.

Metaxalone is a muscle relaxant for oral administration.

Chemically, metaxalone is 5-[(3,5- dimethylphenoxy) methyl]-2-oxazolidinone. The molecular formula is C12H15NO3, which corresponds to a molecular weight of 221.25 g/mol. The structural formula is:

Metaxalone, USP is a white to almost white, crystalline powder freely soluble in chloroform, soluble in methanol and in alcohol, but practically insoluble in ether and in water.
OBJECTIVES: To observe the occurrence of postanaesthetic respiratory complications and to determine their prevalence and risk factors in dogs undergoing brachycephalic obstructive airway syndrome surgery.
MATERIALS AND METHODS: Data from 199 clinical records were retrospectively analysed. Univariable logistic regression followed by multivariable logistic regression was used to identify associations between the dependent variables (set as the postoperative respiratory complications observed in the study dogs) and various independent covariates. The quality of model-fit was assessed using the likelihood ratio test. P≤0.05 was considered statistically significant.
RESULTS: Four postoperative respiratory complications were observed: hypoxaemia (n=10/199; 5%), dyspnoea requiring tracheal re-intubation (n=13/199, 7%), dyspnoea requiring tracheostomy (n=10/199, 5%) and aspiration pneumonia (n=12/199, 6%). Univariable logistic regression showed an association between postoperative aspiration pneumonia and increasing body condition score and American Society of Anaesthesiology classification; however, when these covariates were evaluated in the multivariable model significance was not maintained. Risk factors for tracheostomy were preoperative and postoperative aspiration pneumonia (odds ratio: 9.52, 95% confidence interval: 1.56 to 57.93) and increasing brachycephalic obstructive airway syndrome grade (odds ratio: 4.65, 95% confidence interval: 0.79 to 27.50).
CLINICAL SIGNIFICANCE: High brachycephalic obstructive airway syndrome grade and aspiration pneumonia, either developing peri-operatively or as pre-existing condition, may represent risk factors for postoperative tracheostomy. Preoperative diagnosis of aspiration pneumonia may further increase the risk of postoperative complications.
The software platform is a novel digital delivery system for rehabilitation services comprising educational content, exercise program management and management of patient data. The platform includes a delivery system for standardised evidenced based education modules related to rehabilitation, which can be tailored for specific populations. The system facilitates manual and programmatic electronic collection, management and reporting of patient data. Programs are facilitated through the ability to select, create and modify a library of modules. The standardised management of patient data includes a method for program enrolment and management improving patient acquisition and customer relationship management tools to improve patient retention. Regular patient progress reports are provided to the patient, caregivers and associated third parties in their preferred format. Patient enrolled Clinician completes initial assessment of patient Patient data is recorded at start of and during each session 803 Patient joins education session in related field 804 System sends thanks for coming and follow up info via e-mail or SMS805 Anonymous data available for research partners 806 Reports are available for clinical staff 807 Reports are available for patient and caregivers 808 System allows export or sync to Electronic Medical Record 809
Ovarian cancer is one of the most lethal malignant tumors, characterized by high incidence and poor prognosis. Patients relapse occurred in 65-80% after initial treatment. To date, no effective treatment has been established for these patients. Recently, CD47 has been considered as a promising immunotherapy target. In this paper, we reviewed the biological roles of CD47 in ovarian cancer and summarized the related mechanisms. For most types of cancers, the CD47/Sirpα immune checkpoint has attracted the most attention in immunotherapy. Notably, CD47 monoclonal antibodies and related molecules are promising in the immunotherapy of ovarian cancer, and further research is needed. In the future, new immunotherapy regimens targeting CD47 can be applied to the clinical treatment of ovarian cancer patients.
Kidney stone disease has a multifactorial etiology, and evolving dietary habits necessitate continuous updates on the impact of dietary components on lithogenesis. The relationship between diseases influenced by lifestyle, such as obesity and diabetes, and kidney stone risk underscores the need for comprehensive lifestyle analysis. Effective management of kidney stones requires a multidisciplinary approach, involving collaboration among nutritionists, urologists, nephrologists, and other healthcare professionals to address the complex interactions between diet, lifestyle, and individual susceptibility. Personalized dietary therapy, based on each patient's unique biochemical and dietary profile, is essential and necessitates comprehensive nutritional assessments. Accurate dietary intake evaluation is best achieved through seven-day, real-time dietary records. Key factors influencing urinary risk include fluid intake, dietary protein, carbohydrates, oxalate, calcium, and sodium chloride. Personalized interventions, such as customized dietary changes based on gut microbiota, may improve stone prevention and recurrence. Current research suggests individualized guidance on alcohol intake and indicates that tea and coffee consumption might protect against urolithiasis. There is potential evidence linking tobacco use and secondhand smoke to increased kidney stone risk. The effects of vitamins and physical activity on kidney stone risk remain unresolved due to mixed evidence. For diseases influenced by lifestyle, conclusive evidence on targeted interventions for nephrolithiasis prevention is lacking, though preliminary research suggests potential benefits. Management strategies emphasize lifestyle modifications to reduce recurrence risks, support rapid recovery, and identify predisposing conditions, highlighting the importance of these changes despite inconclusive data.
This is a Phase I, open-label (all people involved know the identity of the intervention), single center trial in healthy HIV negative volunteers to investigate the pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body, the rate at which a drug action begins, the duration of the effect, the chemical changes of the substance in the body, and the effects and routes of excretion of the metabolites) of the drug of rilpivirine (TMC278) 25 mg once daily (q.d.). An approximate total of 20 volunteers will be enrolled in this trial. All volunteers will receive 3 different treatments; o Treatment A: TMC278 25 mg q.d. administered for 14 days.; o Treatment B: efavirenz (EFV) 600 mg q.d. administered for 14 days.; o Treatment C: TMC278 25 mg q.d. administered for 28 days (4 weeks).; All volunteers will start with Treatment A followed by Treatment B. Treatments A and B will be separated by a washout period of at least 14 days but no more than 21 days. At the end of Treatment B, volunteers will continue with Treatment C. There will be no washout period between Treatments B and C.; Full pharmacokinetic profiles of TMC278 will be determined up to 24 hours postdose on Days 1 and 14 of Treatment A (references), Day 1 (immediately after cessation of EFV intake) of Treatment C (test), and on Days 14, 21, and 28 (2, 3, and 4 weeks after cessation of EFV intake, respectively) of Treatment C. Trough (C0h) samples for determination of TMC278 plasma; concentrations will be collected regularly in between. Blood samples for determination of EFV plasma concentrations will be collected at regular time points during Treatment B and during Treatment C after cessation of EFV intake.; Serum samples for potential future testing of ex vivo antiviral activity will be collected and stored.; A pharmacogenomic blood sample for potential future CYP2B6 genotyping will be collected and stored from subjects who consent separately to the pharmacogenomic component of the trial.; Safety and tolerability will be evaluated throughout the trial. Rilpivirine (TMC278) 25mg once daily for 14 days, No Treatment 14-21 days, Efavirenz 600mg once daily for 14 days, TMC278 25mg once daily for 28 days
The invention discloses a traditional Chinese medicine composition for treating verruca plana. The composition comprises the following components by weight: 8 to 10g of angelica sinensis, 9 to 11g of root of common peony, 8 to 10g of tribulus terrestris l plant, 7 to 8g of Chinese scholar tree branch, 5 to 7g of gallnut, 14 to 16g of cherry stone, 24 to 26g of herba portulacae, 9 to 11g of poria cocos and 14 to 16g of ebony carbon. The composition has the functions of nourishing blood, dispelling wind-evil, resolving dampness and expelling toxin, and has a good effect for treating the verruca plana. The effective rate can reach 100%. Any scars cannot be left after the verruca plana is cured. In addition, the composition is rapid in effect and cannot generate any toxic and side effect.
Objective. Over the past decade, neural electrodes have played a crucial role in bridging biological tissues with electronic and robotic devices. This study focuses on evaluating the optimal tip profile and insertion speed for effectively implanting Paradromics' high-density fine microwire arrays (FμA) prototypes into the primary visual cortex (V1) of mice and rats, addressing the challenges associated with the 'bed-of-nails' effect and tissue dimpling.Approach. Tissue response was assessed by investigating the impact of electrodes on the blood-brain barrier (BBB) and cellular damage, with a specific emphasis on tailored insertion strategies to minimize tissue disruption during electrode implantation.Main results.Electro-sharpened arrays demonstrated a marked reduction in cellular damage within 50μm of the electrode tip compared to blunt and angled arrays. Histological analysis revealed that slow insertion speeds led to greater BBB compromise than fast and pneumatic methods. Successful single-unit recordings validated the efficacy of the optimized electro-sharpened arrays in capturing neural activity.Significance.These findings underscore the critical role of tailored insertion strategies in minimizing tissue damage during electrode implantation, highlighting the suitability of electro-sharpened arrays for long-term implant applications. This research contributes to a deeper understanding of the complexities associated with high-channel-count microelectrode array implantation, emphasizing the importance of meticulous assessment and optimization of key parameters for effective integration and minimal tissue disruption. By elucidating the interplay between insertion parameters and tissue response, our study lays a strong foundation for the development of advanced implantable devices with a reduction in reactive gliosis and improved performance in neural recording applications.
The invention provides a method for extracting xanthohumol from hop and an obtained product thereof. The method mainly comprises the following steps: pulverized hop is extracted through supercritical carbon dioxide; a hop raffinate is collected and is subjected to ultrasonic extraction through methanol (ethanol) as an extractant; an extraction solution is condensed, is evenly mixed with diatomite and is successively eluted by two kinds of eluants; and the collected eluant is subjected to filtering and low-temperature condensation treatment to obtain the pure xanthohumol product. The purity of the obtained xanthohumol is 86.2 percent. The purified xanthohumol is a yellow powdery solid; and after the purified xanthohumol is recrystallized, the purity can reach over 97.8 percent. The method can achieve the functions of simplifying the xanthohumol extraction process and reducing the cost for purifying the xanthohumol. The obtained xanthohumol can be widely used in medicine, chemical engineering, food and other fields.
1. The goal of this project is to evaluate the success of pharmacists in delivering the SCRIPT smoking cessation program. The research questions that need to be addressed are: i. What is the quit rate of pregnant women in the Spokane area who receive the SCRIPT intervention delivered by a pharmacist? ii. How does this quit rate compare to the quit rates of other SCRIPT programs given by other health care providers (social workers, nurses, etc.)? iii. Does the SCRIPT intervention have a significant effect on quit rates for smoking pregnant women compared to current Spokane county quit rates?